Aankondiging • Mar 25
AlzChem Group AG, Annual General Meeting, May 05, 2026 AlzChem Group AG, Annual General Meeting, May 05, 2026, at 10:00 W. Europe Standard Time. Aankondiging • Feb 28
AlzChem Group AG announces Annual dividend, payable on May 08, 2026 AlzChem Group AG announced Annual dividend of EUR 2.1000 per share payable on May 08, 2026, ex-date on May 06, 2026 and record date on May 07, 2026. Aankondiging • Sep 24
AlzChem Group AG to Report Q3, 2025 Results on Oct 30, 2025 AlzChem Group AG announced that they will report Q3, 2025 results on Oct 30, 2025 Aankondiging • May 09
AlzChem Group AG to Report First Half, 2025 Results on Jul 30, 2025 AlzChem Group AG announced that they will report first half, 2025 results on Jul 30, 2025 Aankondiging • May 02
AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025 AlzChem Group AG confirmed earnings guidance for the fiscal year 2025. For the year, the Group sales are expected to grow by approximately 5% compared with the previous year. Aankondiging • Mar 29
AlzChem Group AG, Annual General Meeting, May 08, 2025 AlzChem Group AG, Annual General Meeting, May 08, 2025, at 10:00 W. Europe Standard Time. Aankondiging • Dec 06
Alzchem Group Ag Appoints Martina Spitzer as A New Member of the Management Board, Effective from January 1, 2025 AlzChem Group AG approved the appointment of Martina Spitzer as a new member of the Management Board for a term of three years from January 1, 2025 to December 31, 2027. In her new position as Chief Sales Officer (CSO), she will be responsible for the areas of Health & Nutrition (Creapure®), Fine Chemicals (Chemicals & Applications) and Sustainability (ESG). Ms. Spitzer’s appointment as CSO represents the next important step in the early succession planning for the Management Board. Ms. Spitzer is now already taking over two important business areas in sales, as Dr. Weichselbaumer will be in charge of the future project of setting up production in the USA. Ms. Spitzer has been with the Alzchem Group since 1999. In 2020, she was appointed Head of Alzchem’s entire chemical sales division, before she shifted her focus to strategic corporate development and ESG in 2022 after around 15 years in sales. In this role, she was instrumental in the introduction of the sustainability division, the optimization of central business processes and the implementation of forward-looking projects. Aankondiging • Nov 27
AlzChem Group AG to Report Q1, 2025 Results on Apr 30, 2025 AlzChem Group AG announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Nov 09
Third quarter 2024 earnings released: EPS: €1.22 (vs €0.85 in 3Q 2023) Third quarter 2024 results: EPS: €1.22 (up from €0.85 in 3Q 2023). Revenue: €132.7m (up 7.0% from 3Q 2023). Net income: €12.4m (up 44% from 3Q 2023). Profit margin: 9.3% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Nov 08
AlzChem Group AG to Report Fiscal Year 2024 Results on Feb 28, 2025 AlzChem Group AG announced that they will report fiscal year 2024 results on Feb 28, 2025 Price Target Changed • Oct 23
Price target increased by 13% to €71.78 Up from €63.65, the current price target is an average from 4 analysts. New target price is 24% above last closing price of €57.80. Stock is up 196% over the past year. The company is forecast to post earnings per share of €4.97 for next year compared to €3.40 last year. Price Target Changed • Oct 11
Price target increased by 7.7% to €66.03 Up from €61.30, the current price target is an average from 4 analysts. New target price is 22% above last closing price of €54.20. Stock is up 170% over the past year. The company is forecast to post earnings per share of €4.92 for next year compared to €3.40 last year. Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €52.40, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry in Germany. Total returns to shareholders of 150% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.85 per share. Buy Or Sell Opportunity • Sep 30
Now 23% overvalued Over the last 90 days, the stock has fallen 1.9% to €47.30. The fair value is estimated to be €38.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 10% in 2 years. Earnings are forecast to grow by 23% in the next 2 years. Valuation Update With 7 Day Price Move • Sep 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €41.50, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 13x in the Chemicals industry in Germany. Total returns to shareholders of 91% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.38 per share. Price Target Changed • Aug 19
Price target increased by 13% to €61.30 Up from €54.05, the current price target is an average from 4 analysts. New target price is 18% above last closing price of €52.00. Stock is up 154% over the past year. The company is forecast to post earnings per share of €4.93 for next year compared to €3.40 last year. Price Target Changed • Aug 06
Price target increased by 7.5% to €56.05 Up from €52.15, the current price target is an average from 4 analysts. New target price is 21% above last closing price of €46.30. Stock is up 148% over the past year. The company is forecast to post earnings per share of €4.52 for next year compared to €3.40 last year. Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: €0.71 (vs €0.70 in 2Q 2023) Second quarter 2024 results: EPS: €0.71 (up from €0.70 in 2Q 2023). Revenue: €139.9m (up 5.2% from 2Q 2023). Net income: €14.4m (up 100% from 2Q 2023). Profit margin: 10% (up from 5.4% in 2Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Aug 02
AlzChem Group AG to Report Q3, 2024 Results on Nov 07, 2024 AlzChem Group AG announced that they will report Q3, 2024 results on Nov 07, 2024 Price Target Changed • Jul 30
Price target increased by 9.4% to €54.05 Up from €49.40, the current price target is an average from 4 analysts. New target price is 9.2% above last closing price of €49.50. Stock is up 159% over the past year. The company is forecast to post earnings per share of €4.30 for next year compared to €3.40 last year. New Risk • Jul 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.0% average weekly change). Price Target Changed • May 15
Price target increased by 15% to €49.40 Up from €43.10, the current price target is an average from 4 analysts. New target price is 12% above last closing price of €44.00. Stock is up 122% over the past year. The company is forecast to post earnings per share of €4.03 for next year compared to €3.40 last year. Aankondiging • May 09
AlzChem Group AG to Report First Half, 2024 Results on Aug 01, 2024 AlzChem Group AG announced that they will report first half, 2024 results on Aug 01, 2024 Reported Earnings • May 01
First quarter 2024 earnings released: EPS: €1.20 (vs €0.76 in 1Q 2023) First quarter 2024 results: EPS: €1.20 (up from €0.76 in 1Q 2023). Revenue: €153.6m (up 1.4% from 1Q 2023). Net income: €12.2m (up 59% from 1Q 2023). Profit margin: 7.9% (up from 5.1% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €43.50, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Chemicals industry in Germany. Total returns to shareholders of 101% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €71.69 per share. Declared Dividend • Mar 28
Dividend increased to €1.20 Dividend of €1.20 is 14% higher than last year. Ex-date: 8th May 2024 Payment date: 10th May 2024 Dividend yield will be 3.2%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 1.5% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Price Target Changed • Mar 07
Price target increased by 7.9% to €37.35 Up from €34.63, the current price target is an average from 4 analysts. New target price is 25% above last closing price of €30.00. Stock is up 60% over the past year. The company is forecast to post earnings per share of €3.83 for next year compared to €3.40 last year. Price Target Changed • Mar 04
Price target increased by 7.9% to €35.60 Up from €33.00, the current price target is an average from 4 analysts. New target price is 31% above last closing price of €27.10. Stock is up 38% over the past year. The company is forecast to post earnings per share of €3.77 for next year compared to €3.40 last year. Price Target Changed • Dec 05
Price target increased by 9.1% to €34.63 Up from €31.75, the current price target is an average from 4 analysts. New target price is 40% above last closing price of €24.70. Stock is up 36% over the past year. The company is forecast to post earnings per share of €3.51 for next year compared to €2.96 last year. Aankondiging • Nov 30
AlzChem Group AG to Report Q1, 2024 Results on Apr 30, 2024 AlzChem Group AG announced that they will report Q1, 2024 results on Apr 30, 2024 Price Target Changed • Nov 10
Price target increased by 9.3% to €33.00 Up from €30.20, the current price target is an average from 4 analysts. New target price is 42% above last closing price of €23.30. Stock is up 40% over the past year. The company is forecast to post earnings per share of €3.31 for next year compared to €2.96 last year. New Risk • Oct 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.5% average weekly change). Reported Earnings • Oct 29
Third quarter 2023 earnings released: EPS: €0.85 (vs €0.58 in 3Q 2022) Third quarter 2023 results: EPS: €0.85 (up from €0.58 in 3Q 2022). Revenue: €123.9m (down 15% from 3Q 2022). Net income: €8.61m (up 45% from 3Q 2022). Profit margin: 7.0% (up from 4.1% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Aankondiging • Oct 27
AlzChem Group AG to Report Fiscal Year 2023 Results on Mar 01, 2024 AlzChem Group AG announced that they will report fiscal year 2023 results on Mar 01, 2024 Aankondiging • Sep 19
AlzChem Group AG to Report Q3, 2023 Results on Oct 26, 2023 AlzChem Group AG announced that they will report Q3, 2023 results on Oct 26, 2023 Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €22.00, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 13x in the Chemicals industry in Germany. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.19 per share. New Risk • Aug 04
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 42% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Dividend is not well covered by cash flows (138% cash payout ratio). Reported Earnings • Aug 03
Second quarter 2023 earnings released: EPS: €0.71 (vs €0.95 in 2Q 2022) Second quarter 2023 results: EPS: €0.71 (down from €0.95 in 2Q 2022). Revenue: €128.5m (down 14% from 2Q 2022). Net income: €7.20m (down 25% from 2Q 2022). Profit margin: 5.6% (down from 6.5% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • May 06
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: EPS: €0.76 (down from €0.76 in 1Q 2022). Revenue: €156.0m (up 19% from 1Q 2022). Net income: €7.67m (flat on 1Q 2022). Profit margin: 4.9% (down from 5.9% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 23%. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Aankondiging • May 05
AlzChem Group AG to Report First Half, 2023 Results on Aug 03, 2023 AlzChem Group AG announced that they will report first half, 2023 results on Aug 03, 2023 Upcoming Dividend • May 05
Upcoming dividend of €1.05 per share at 5.5% yield Eligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. Payout ratio is a comfortable 35% but the company is not cash flow positive. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.7%). In line with average of industry peers (5.6%). Price Target Changed • Mar 21
Price target increased by 8.7% to €29.58 Up from €27.20, the current price target is an average from 4 analysts. New target price is 57% above last closing price of €18.85. Stock is down 21% over the past year. The company posted earnings per share of €2.96 last year. Reported Earnings • Mar 01
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: €2.96 (up from €2.72 in FY 2021). Revenue: €566.4m (up 32% from FY 2021). Net income: €30.1m (up 8.9% from FY 2021). Profit margin: 5.3% (down from 6.4% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 18%. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 15% share price gain to €17.85, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 10% over the past three years. Aankondiging • Dec 09
AlzChem Group AG, Annual General Meeting, May 11, 2023 AlzChem Group AG, Annual General Meeting, May 11, 2023, at 10:00 Central European Standard Time. Price Target Changed • Nov 16
Price target decreased to €26.05 Down from €29.43, the current price target is an average from 4 analysts. New target price is 55% above last closing price of €16.85. Stock is down 28% over the past year. The company is forecast to post earnings per share of €2.40 for next year compared to €2.72 last year. Reported Earnings • Oct 28
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: €0.59 (up from €0.46 in 3Q 2021). Revenue: €145.1m (up 48% from 3Q 2021). Net income: €5.93m (up 27% from 3Q 2021). Profit margin: 4.1% (down from 4.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) also surpassed analyst estimates by 69%. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Aankondiging • Oct 27
AlzChem Group AG to Report Fiscal Year 2022 Final Results on Feb 28, 2023 AlzChem Group AG announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Feb 28, 2023 Price Target Changed • Oct 20
Price target decreased to €26.05 Down from €29.43, the current price target is an average from 4 analysts. New target price is 73% above last closing price of €15.05. Stock is down 33% over the past year. The company is forecast to post earnings per share of €2.55 for next year compared to €2.72 last year. Reported Earnings • Jul 27
Second quarter 2022 earnings released: EPS: €0.95 (vs €0.90 in 2Q 2021) Second quarter 2022 results: EPS: €0.95 (up from €0.90 in 2Q 2021). Revenue: €142.4m (up 26% from 2Q 2021). Net income: €9.59m (up 4.5% from 2Q 2021). Profit margin: 6.7% (down from 8.1% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.7%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • May 11
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: €0.76 (down from €0.78 in 1Q 2021). Revenue: €133.5m (up 25% from 1Q 2021). Net income: €7.70m (down 2.4% from 1Q 2021). Profit margin: 5.8% (down from 7.4% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 9.9%. Over the next year, revenue is forecast to grow 8.7%, compared to a 6.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • Apr 29
Upcoming dividend of €1.00 per share Eligible shareholders must have bought the stock before 06 May 2022. Payment date: 10 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 4.5%. Within top quartile of German dividend payers (4.0%). In line with average of industry peers (4.9%). Reported Earnings • Feb 25
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: €2.72 (up from €1.94 in FY 2020). Revenue: €433.7m (up 12% from FY 2020). Net income: €27.6m (up 40% from FY 2020). Profit margin: 6.4% (up from 5.1% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 4.1%, compared to a 6.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS €0.46 (vs €0.37 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €98.1m (up 17% from 3Q 2020). Net income: €4.69m (up 25% from 3Q 2020). Profit margin: 4.8% (up from 4.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Price Target Changed • Aug 09
Price target increased to €32.25 Up from €28.50, the current price target is an average from 2 analysts. New target price is 31% above last closing price of €24.70. Stock is up 23% over the past year. Reported Earnings • Aug 06
Second quarter 2021 earnings released: EPS €0.66 (vs €0.66 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €113.5m (up 6.5% from 2Q 2020). Net income: €9.17m (up 37% from 2Q 2020). Profit margin: 8.1% (up from 6.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year and the company’s share price has also fallen by 6% per year. Reported Earnings • May 07
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €108.3m (up 13% from 1Q 2020). Net income: €7.89m (up 80% from 1Q 2020). Profit margin: 7.3% (up from 4.6% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Upcoming Dividend • May 06
Upcoming dividend of €0.77 per share Eligible shareholders must have bought the stock before 13 May 2021. Payment date: 18 May 2021. Trailing yield: 3.1%. Within top quartile of German dividend payers (3.1%). Lower than average of industry peers (3.5%). Reported Earnings • Mar 20
Full year 2020 earnings released: EPS €1.94 (vs €1.77 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €389.9m (up 1.3% from FY 2019). Net income: €19.7m (up 9.6% from FY 2019). Profit margin: 5.1% (up from 4.7% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 25
New 90-day high: €24.50 The company is up 19% from its price of €20.60 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €43.68 per share. Aankondiging • Jan 16
AlzChem Group AG to Report Fiscal Year 2020 Results on Mar 19, 2021 AlzChem Group AG announced that they will report fiscal year 2020 results on Mar 19, 2021 Analyst Estimate Surprise Post Earnings • Nov 12
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 4.9%, compared to a 3.6% growth forecast for the Chemicals industry in Germany. Reported Earnings • Nov 12
Third quarter 2020 earnings released: EPS €0.37 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €84.1m (down 18% from 3Q 2019). Net income: €3.76m (down 25% from 3Q 2019). Profit margin: 4.5% (down from 4.9% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 78% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Aankondiging • Nov 07
AlzChem Group AG Expands Nitrile Production by 50% AlzChem Group AG consistently continues its growth and investment strategy even in the current environment. Due to the continuing high level of market demand, nitrile production will be expanded by up to 50% by the second quarter of 2021. The investment volume amounts to approximately EUR 12 million. The currently available capacities had only been expanded as of July 2019 and quickly reached 100% capacity. The additional nitrile production capacities are intended to primarily support the growth of medications and biocides. AlzChem takes advantage of the market trend towards more robust supply chains, thus following the trend of increased supply security through a European supplier. The expanded nitrile production plant is again based on AlzChem's proven gas phase technology, which is continuously being optimized by AlzChem engineers and chemists and which sets the standards in terms of raw material yield and environmental aspects. Is New 90 Day High Low • Oct 30
New 90-day low: €17.50 The company is down 4.0% from its price of €18.15 on 31 July 2020. The German market is also down 4.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €41.80 per share. Aankondiging • Oct 15
AlzChem Group AG Revises Consolidated Sales Guidance for the Fiscal Year 2020 AlzChem Group AG revised consolidated sales guidance for the fiscal year 2020. Due to the continuing economic effects of the COVID-19 pandemic in individual target industries and regions, AlzChem Group AG adjusts its forecast for fiscal year 2020. The company now expects to generate stable to slightly declining consolidated sales compared to the previous year (original forecast: slightly rising to sharply rising). Aankondiging • Sep 12
AlzChem Group AG to Report Q1, 2021 Results on May 06, 2021 AlzChem Group AG announced that they will report Q1, 2021 results on May 06, 2021